Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gene Activator Protein May Be Key to Controlling Schistosomiasis

By LabMedica International staff writers
Posted on 16 Jan 2012
Parasitologists have identified a gene activator protein in Schistosoma mansoni that spurs development of the parasite after infection of its human host and is an attractive target for a new generation of drugs to control this disease.

Schistosome parasites infect more than 200 million people worldwide and cause human schistosomiasis. More...
Free-swimming schistosome larvae are highly mobile, and invade and penetrate the host's skin to perpetuate their lifecycle in their human host, growing from 90-215 µm in length as a schistosomulum to a 7-20 mm long adult worm. Few molecular pathways have been identified in schistosome worms that are important for parasite early development.

In the current study, investigators at Case Western Reserve University (Cleveland, OH, USA) focused on the gene activator protein myocyte enhancer factor 2 protein (Mef2). This protein a major regulator of muscle and nerve development in mammals and insects and is highly conserved from bread yeast to vertebrates.

They reported in the January 3, 2012, online edition of the journal PLoS Neglected Tropical Diseases that quantitative PCR demonstrated that Mef2 was expressed during several stages of schistosome development, and that it could bind to conserved Mef2 DNA consensus binding sequences. SmMef2 was shown to be a transactivator that could induce transcription of four separate heterologous reporter genes by yeast one-hybrid analysis.

The intent is to seek out drugs to target SMfe2. Although Mef2 is present in humans, the portion of SMef2 that switches on gene activity is so different from human Mef2 that it should be possible to target that part, and not affect the host.

“This is really a disease of poor people," said senior author Dr. Emmitt Jolly, professor of biology at Case Western Reserve University. “The strategy to combat the disease cannot be expensive.”

Related Links:

Case Western Reserve University



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.